$14.12
-0.20-1.40%
At close: -
$14.12
0.000.00%
After Hours: 4:01 PM EDT
Comments
Loading...
Inhibrx Biosciences Earnings Estimates, EPS & Revenue | NASDAQ:INBX | Benzinga
Inhibrx Biosciences reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
May 8
EPS Estimate
$-3.450
Quarterly Revenue Estimate
–
Annual Revenue
(as of Dec 31)
(as of Dec 31)
$200.00K
Analyze the earnings history of Inhibrx Biosciences using advanced sorting and filters.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| INBX | Inhibrx | -$1.44 | -$3.45 | — | — | $0.00 | — | — | — | 05/08/2025 | Get Alert |
| INBX | Inhibrx Biosciences | -$6.93 | — | -$3.09 | — | $1.63M | — | $100.00K | — | 03/17/2025 | Get Alert |
| INBX | Inhibrx Biosciences | -$4.39 | -$3.38 | -$2.84 | 15.98% | $119.00K | — | $0.00 | — | 11/14/2024 | Get Alert |
| INBX | Inhibrx Biosciences | -$4.31 | -$1.47 | $125.48 | 8636.05% | $30.00K | — | $100.00K | — | 08/13/2024 | Get Alert |
| INBX | Inhibrx | -$1.12 | -$1.51 | -$1.44 | 4.64% | $17.00K | — | $0.00 | — | 05/09/2024 | Get Alert |
| INBX | Inhibrx | -$0.95 | -$1.04 | -$1.73 | -66.35% | $274.00K | $50.00K | $1.63M | 3168.00% | 02/28/2024 | Get Alert |
| INBX | Inhibrx | -$0.90 | -$1.01 | -$1.10 | -8.91% | $278.00K | — | $119.00K | — | 11/09/2023 | Get Alert |
| INBX | Inhibrx | -$0.97 | -$1.03 | -$1.08 | -4.85% | $711.00K | — | $30.00K | — | 08/07/2023 | Get Alert |
| INBX | Inhibrx | -$0.80 | -$0.84 | -$1.12 | -33.33% | $929.00K | $150.00K | $17.00K | -88.67% | 05/08/2023 | Get Alert |
| INBX | Inhibrx | -$0.55 | -$0.79 | -$0.95 | -20.25% | $2.86M | $790.00K | $274.00K | -65.32% | 03/06/2023 | Get Alert |
| INBX | Inhibrx | -$0.54 | -$0.94 | -$0.90 | 4.26% | $2.53M | $630.00K | $278.00K | -55.87% | 11/07/2022 | Get Alert |
| INBX | Inhibrx | -$0.55 | -$0.78 | -$0.97 | -24.36% | $954.00K | $1.07M | $711.00K | -33.55% | 08/08/2022 | Get Alert |
| INBX | Inhibrx | -$0.51 | — | -$0.80 | — | $889.00K | — | $929.00K | — | 05/09/2022 | Get Alert |
| INBX | Inhibrx | -$0.47 | — | -$0.55 | — | $2.78M | — | $2.86M | — | 02/28/2022 | Get Alert |
| INBX | Inhibrx | -$0.77 | -$0.57 | -$0.54 | 5.26% | $5.90M | $1.00M | $2.53M | 153.20% | 11/09/2021 | Get Alert |
| INBX | Inhibrx | -$0.99 | -$0.56 | -$0.55 | 1.79% | — | $820.00K | $954.00K | 16.34% | 08/09/2021 | Get Alert |
| INBX | Inhibrx | -$1.11 | -$0.56 | -$0.51 | 8.93% | — | $920.00K | $889.00K | -3.37% | 05/13/2021 | Get Alert |
| INBX | Inhibrx | — | — | -$0.47 | — | — | — | $2.78M | — | 03/12/2021 | Get Alert |
| INBX | Inhibrx | -$1.11 | -$0.60 | -$0.77 | -28.33% | $1.22M | $1.00M | $5.90M | 490.10% | 11/13/2020 | Get Alert |
Inhibrx Biosciences (INBX) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | 2024-11-14 | $-2.84 | $-3.38 | 16.0 % |
| Q2 | 2024-08-13 | $125.48 | $-1.47 | 8636.0 % |
| Q1 | 2024-05-09 | $-1.44 | $-1.51 | 4.64 % |
| Q4 | 2024-02-28 | $-1.73 | $-1.04 | -66.3 % |
Inhibrx Biosciences (INBX) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q4 | 2024-02-28 | $1.63M | $50.00K | 3168.0 % |
| Q1 | 2023-05-08 | $17.00K | $150.00K | -88.7 % |
| Q4 | 2023-03-06 | $274.00K | $790.00K | -65.3 % |
| Q3 | 2022-11-07 | $278.00K | $630.00K | -55.9 % |
FAQ
When is Inhibrx Biosciences (NASDAQ:INBX) reporting earnings?
Inhibrx Biosciences (INBX) is scheduled to report earnings on May 8, 2025. The last reported earnings were for reported on March 17, 2025 for Q4.
What were the latest earnings per share (EPS) for Inhibrx Biosciences (NASDAQ:INBX)?
The Actual EPS was $-3.09, which missed the estimate of $0.00.
What were Inhibrx Biosciences’s (NASDAQ:INBX) revenues?
The Actual Revenue was $100K, which beat the estimate of $0K.
Browse earnings estimates, EPS, and revenue on all stocks.